Small Cell Lung Cancer

Seminars in Respiratory and Critical Care Medicine

Volumn 37, Issue 5, 2016, Pages 783-796

  Kalemkerian, Gregory P ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

cancer staging; chemotherapy; immunotherapy; incidence; lung cancer; positron emission tomography; radiotherapy; small cell lung carcinoma

Indexed keywords

AMRUBICIN; BENDAMUSTINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; IPILIMUMAB; IRINOTECAN; METHOTREXATE; NAVELBINE; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PLACEBO; ROVALPITUZUMAB TESIRINE; SUNITINIB; TEMOZOLOMIDE; TOPOTECAN; VANDETANIB; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE METASTASIS; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; GASTROINTESTINAL TOXICITY; HUMAN; LONG TERM SURVIVAL; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RECOMMENDED DRUG DOSE; SKULL IRRADIATION; SMALL CELL LUNG CANCER; SMOKING; TRACHEOESOPHAGEAL FISTULA; VOMITING; DIAGNOSTIC IMAGING; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; RADIOTHERAPY;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; QUALITY OF LIFE; RADIOTHERAPY; SMALL CELL LUNG CARCINOMA;

EID: 84991730134     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0036-1592116     Document Type: Article

References (119)

1. Pesch B Kendzia B Gustavsson P, et al. Cigarette smoking and lung cancer - relative risk estimates for the major histological types from a pooled analysis of case-control studies Int J Cancer 2012 131 5 1210 1219
2. Churg A Lung cancer cell type and occupational exposure In: Samet J M, ed. Epidemiology of Lung Cancer Marcel Dekker New York 1994 413 436
3. Navada S Lai P Schwartz A G Kalemkerian G P Temporal trends in small cell lung cancer: analysis of the National Surveillance, Epidemiology, and End-Results database J Clin Oncol 2006 24 (18S): 384s [abstract 7082]
4. Govindan R Page N Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 2006 24 28 4539 4544
5. Siegel R L Miller K D Jemal A Cancer statistics, 2015 CA Cancer J Clin 2015 65 1 5 29
6. Zelen M Keynote address on biostatistics and data retrieval Cancer Chemother Rep 3 1973 4 2 31 42
7. Stahel R A Ginsberg R Havemann K, et al. Staging and prognostic factors in small cell lung cancer: a consensus report Lung Cancer 1989 5 119 126
8. Micke P Faldum A Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - what limits limited disease? Lung Cancer 2002 37 3 271 276
9. American Joint Committee on Cancer AJCC Cancer Staging Handbook, 7th ed New York Springer 2010 299 323
10. Shepherd F A Crowley J Van Houtte P, et al. The IASLC Lung Cancer Staging Project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer J Thorac Oncol 2007 2 1067 1077
11. Goldstraw P Crowley J Chansky K, et al; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2007 2 8 706 714
12. Vallières E Shepherd F A Crowley J, et al; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer J Thorac Oncol 2009 4 9 1049 1059
13. Ignatius Ou S H Zell J A The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition J Thorac Oncol 2009 4 3 300 310
14. Hochstenbag M M Twijnstra A Wilmink J T Wouters E F ten Velde G P Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis J Neurooncol 2000 48 3 243 248
15. Seute T Leffers P Wilmink J T ten Velde G P Twijnstra A Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy J Clin Oncol 2006 24 13 2079 2083
16. Campling B Quirt I DeBoer G Feld R Shepherd F A Evans W K Is bone marrow examination in small-cell lung cancer really necessary? Ann Intern Med 1986 105 4 508 512
17. Tritz D B Doll D C Ringenberg Q S, et al. Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables Cancer 1989 63 4 763 766
18. Levitan N Byrne R E Bromer R H, et al. The value of the bone scan and bone marrow biopsy staging small cell lung cancer Cancer 1985 56 3 652 654
19. Kalemkerian G P Loo B W Akerley W, et al. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer, version 1. 2016 Available at: http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
20. Hauber H P Bohuslavizki K H Lund C H Fritscher-Ravens A Meyer A Pforte A Positron emission tomography in the staging of small-cell lung cancer : a preliminary study Chest 2001 119 3 950 954
21. Schumacher T Brink I Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer Eur J Nucl Med 2001 28 4 483 488
22. Shen Y Y Shiau Y C Wang J J Ho S T Kao C H Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer Anticancer Res 2002 22 (2B) 1257 1264
23. Chin R Jr McCain T W Miller A A, et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study Lung Cancer 2002 37 1 1 6
24. Kamel E M Zwahlen D Wyss M T Stumpe K D von Schulthess G K Steinert H C Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer J Nucl Med 2003 44 12 1911 1917
25. Bradley J D Dehdashti F Mintun M A Govindan R Trinkaus K Siegel B A Positron emission tomography in limited-stage small-cell lung cancer: a prospective study J Clin Oncol 2004 22 16 3248 3254
26. Brink I Schumacher T Mix M, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer Eur J Nucl Med Mol Imaging 2004 31 12 1614 1620
27. Blum R MacManus M P Rischin D Michael M Ball D Hicks R J Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience Am J Clin Oncol 2004 27 2 164 171
28. Kut V Spies W Spies S Gooding W Argiris A Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) Am J Clin Oncol 2007 30 1 45 50
29. Fischer B M Mortensen J Langer S W, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis Ann Oncol 2007 18 2 338 345
30. Niho S Fujii H Murakami K, et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer Lung Cancer 2007 57 3 328 333
31. Vinjamuri M Craig M Campbell-Fontaine A Almubarak M Gupta N Rogers J S Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer 2008 9 1 30 34
32. Azad A Chionh F Scott A M, et al. High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer Mol Imaging Biol 2010 12 4 443 451
33. Jett J R Schild S E Kesler K A Kalemkerian G P Treatment of small cell lung cancer. Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 2013 143 (5 Suppl): e400S e419S
34. Ruben J D Ball D L The efficacy of PET staging for small-cell lung cancer: a systematic review and cost analysis in the Australian setting J Thorac Oncol 2012 7 6 1015 1020
35. Lu Y Y Chen J H Liang J A Chu S Lin W Y Kao C H 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis Nucl Med Commun 2014 35 7 697 703
36. van Loon J De Ruysscher D Wanders R, et al. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study Int J Radiat Oncol Biol Phys 2010 77 2 329 336
37. Hillner B E Siegel B A Shields A F, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry J Nucl Med 2008 49 12 1928 1935
38. Xanthopoulos E P Corradetti M N Mitra N, et al. Impact of PET staging in limited-stage small-cell lung cancer J Thorac Oncol 2013 8 7 899 905
39. Warde P Payne D Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis J Clin Oncol 1992 10 6 890 895
40. Pignon J P Arriagada R Ihde D C, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer N Engl J Med 1992 327 23 1618 1624
41. Fried D B Morris D E Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer J Clin Oncol 2004 22 23 4837 4845
42. De Ruysscher D Pijls-Johannesma M Bentzen S M, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer J Clin Oncol 2006 24 7 1057 1063
43. Turrisi A T III Kim K Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide N Engl J Med 1999 340 4 265 271
44. Bonner J A Sloan J A Shanahan T G, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma J Clin Oncol 1999 17 9 2681 2691
45. Jeremic B Shibamoto Y Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study J Clin Oncol 1999 17 7 2092 2099
46. Slotman B J van Tinteren H Praag J O, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial Lancet 2015 385 9962 36 42
47. Aupérin A Arriagada R Pignon J P, et al; Prophylactic Cranial Irradiation Overview Collaborative Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission N Engl J Med 1999 341 7 476 484
48. Slotman B Faivre-Finn C Kramer G, et al; EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer N Engl J Med 2007 357 7 664 672
49. Slotman B J Mauer M E Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups J Clin Oncol 2009 27 1 78 84
50. Seto T Takahashi T Yamanaka T, et al. Prophylactic cranial irradiation has a detrimental effect on the overall survival of patients with extensive disease small cell lung cancer: results of a Japanese randomized phase III trial J Clin Oncol 2014 32 (15S): [abstract 7503]
51. Greco F A Oldham R K Clinical management of patients with small cell lung cancer In: Greco F A Oldham R K Bunn P A, eds. Small Cell Lung Cancer New York Grune & Stratton 1981 353 379
52. Lowenbraun S Bartolucci A Smalley R V Lynn M Krauss S Durant J R The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma Cancer 1979 44 2 406 413
53. Ihde D C Chemotherapy of lung cancer N Engl J Med 1992 327 20 1434 1441
54. Evans W K Shepherd F A Feld R Osoba D Dang P Deboer G VP-16 and cisplatin as first-line therapy for small-cell lung cancer J Clin Oncol 1985 3 11 1471 1477
55. Fukuoka M Furuse K Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer J Natl Cancer Inst 1991 83 12 855 861
56. Roth B J Johnson D H Einhorn L H, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group J Clin Oncol 1992 10 2 282 291
57. Sundstrøm S Bremnes R M Kaasa S, et al; Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up J Clin Oncol 2002 20 24 4665 4672
58. Pujol J L Carestia L Daurès J P Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent Br J Cancer 2000 83 1 8 15
59. Mascaux C Paesmans M Berghmans T, et al; European Lung Cancer Working Party (ELCWP). A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis Lung Cancer 2000 30 1 23 36
60. Noda K Nishiwaki Y Kawahara M, et al; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 2002 346 2 85 91
61. Hanna N Bunn P A Jr Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer J Clin Oncol 2006 24 13 2038 2043
62. Lara P N Jr Natale R Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 J Clin Oncol 2009 27 15 2530 2535
63. Zatloukal P Cardenal F Szczesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease Ann Oncol 2010 21 9 1810 1816
64. Kubota K Hida T Ishikura S, et al; Japan Clinical Oncology Group. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study Lancet Oncol 2014 15 1 106 113
65. Hermes A Bergman B Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial J Clin Oncol 2008 26 26 4261 4267
66. Schmittel A Fischer von Weikersthal L Sebastian M, et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer Ann Oncol 2006 17 4 663 667
67. Eckardt J R von Pawel J Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer J Clin Oncol 2006 24 13 2044 2051
68. Fink T H Huber R M Heigener D F, et al; “Aktion Bronchialkarzinom” (ABC Study Group). Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial J Thorac Oncol 2012 7 9 1432 1439
69. Jiang J Liang X Zhou X, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer J Thorac Oncol 2010 5 6 867 873
70. Lima J P dos Santos L V Sasse E C Lima C S Sasse A D Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis J Thorac Oncol 2010 5 12 1986 1993
71. Thomas P Castelnau O Paillotin D, et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study J Clin Oncol 2001 19 5 1320 1325
72. Lyss A P Herndon J E II Lynch T J Jr, et al. Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430) Clin Lung Cancer 2002 3 3 205 210, discussion 211-212
73. Leyvraz S Pampallona S Martinelli G, et al; Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial J Natl Cancer Inst 2008 100 8 533 541
74. Lorigan P Woll P J O'Brien M ER Ashcroft L F Sampson M R Thatcher N Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer J Natl Cancer Inst 2005 97 9 666 674
75. Furuse K Fukuoka M Nishiwaki Y, et al; The Japan Clinical Oncology Group. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer J Clin Oncol 1998 16 6 2126 2132
76. Niell H B Herndon J E II Miller A A, et al; Cancer and Leukemia Group. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732 J Clin Oncol 2005 23 16 3752 3759
77. Elias A Ibrahim J Skarin A T, et al. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome J Clin Oncol 1999 17 4 1175 1184
78. Rossi A Garassino M C Cinquini M, et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis Lung Cancer 2010 70 2 119 128
79. Schiller J H Adak S Cella D DeVore R F III Johnson D H Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group J Clin Oncol 2001 19 8 2114 2122
80. Hanna N H Einhorn L H Small-cell lung cancer: state of the art Clin Lung Cancer 2002 4 2 87 94
81. Skarlos D V Samantas E Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study Ann Oncol 1994 5 7 601 607
82. Rossi A Di Maio M Chiodini P, et al. Carboplatin-or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data J Clin Oncol 2012 30 14 1692 1698
83. Postmus P E Berendsen H H van Zandwijk N Splinter T A Burghouts J T Bakker W Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy Eur J Cancer Clin Oncol 1987 23 9 1409 1411
84. Giaccone G Ferrati P Donadio M Testore F Calciati A Reinduction chemotherapy in small cell lung cancer Eur J Cancer Clin Oncol 1987 23 11 1697 1699
85. O'Brien M ER Ciuleanu T E Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer J Clin Oncol 2006 24 34 5441 5447
86. von Pawel J Schiller J H Shepherd F A, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer J Clin Oncol 1999 17 2 658 667
87. Pietanza M C Kadota K Huberman K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker Clin Cancer Res 2012 18 4 1138 1145
88. Zauderer M G Drilon A Kadota K, et al. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase Lung Cancer 2014 86 2 237 240
89. Schmittel A Knödler M Hortig P Schulze K Thiel E Keilholz U Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients Lung Cancer 2007 55 1 109 113
90. Lammers P E Shyr Y Li C I, et al. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer J Thorac Oncol 2014 9 4 559 562
91. Yana T Negoro S Takada M, et al; West Japan Thoracic Oncology Group. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study Invest New Drugs 2007 25 3 253 258
92. Onoda S Masuda N Seto T, et al; Thoracic Oncology Research Group Study 0301. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301 J Clin Oncol 2006 24 34 5448 5453
93. Igawa S Yamamoto N Ueda S, et al. Evaluation of the recommended dose and efficacy of amrubicin as second-and third-line chemotherapy for small cell lung cancer J Thorac Oncol 2007 2 8 741 744
94. Ettinger D S Jotte R Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer J Clin Oncol 2010 28 15 2598 2603
95. Satouchi M Kotani Y Shibata T, et al. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509 J Clin Oncol 2014 32 12 1262 1268
96. Inoue A Sugawara S Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402 J Clin Oncol 2008 26 33 5401 5406
97. Jotte R Conkling P Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy J Clin Oncol 2011 29 3 287 293
98. von Pawel J Jotte R Spigel D R, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer J Clin Oncol 2014 32 35 4012 4019
99. Lucchi M Mussi A Fontanini G Faviana P Ribechini A Angeletti C A Small cell lung carcinoma (SCLC): the angiogenic phenomenon Eur J Cardiothorac Surg 2002 21 6 1105 1110
100. Salven P Ruotsalainen T Mattson K Joensuu H High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer Int J Cancer 1998 79 2 144 146
101. Horn L Dahlberg S E Sandler A B, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501 J Clin Oncol 2009 27 35 6006 6011
102. Spigel D R Townley P M Waterhouse D M, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial J Clin Oncol 2011 29 16 2215 2222
103. Ready N E Dudek A Z Pang H H, et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study J Clin Oncol 2011 29 33 4436 4441
104. Spigel D R Hainsworth J D Yardley D A, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab J Clin Oncol 2010 28 1 43 48
105. Ready N E Pang H H Gu L, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study - CALGB 30504 (Alliance) J Clin Oncol 2015 33 15 1660 1665
106. Arnold A M Seymour L Smylie M, et al; National Cancer Institute of Canada Clinical Trials Group Study BR.20. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20 J Clin Oncol 2007 25 27 4278 4284
107. Rudin C M Hann C L Peacock C D Watkins D N Novel systemic therapies for small cell lung cancer J Natl Compr Canc Netw 2008 6 3 315 322
108. Pietanza M C Byers L A Minna J D Rudin C M Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res 2015 21 10 2244 2255
109. Schneider B J Kalemkerian G P Personalized therapy of small cell lung cancer In: Ahmad A Gadgeel S M, eds. Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management New York Springer 2016 149 174
110. Pietanza M C Spigel D Bauer T M, et al. Safety, activity and response durability assessment of single-agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate, in small cell lung cancer European Cancer Congress 2015, Abstract 7LBA
111. Peifer M Fernández-Cuesta L Sos M L, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer Nat Genet 2012 44 10 1104 1110
112. Rudin C M Durinck S Stawiski E W, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer Nat Genet 2012 44 10 1111 1116
113. George J Lim J S Jang S J, et al. Comprehensive genomic profiles of small cell lung cancer Nature 2015 524 7563 47 53
114. Byers L A Wang J Nilsson M B, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1 Cancer Discov 2012 2 9 798 811
115. Sos M L Dietlein F Peifer M, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer Proc Natl Acad Sci U S A 2012 109 42 17034 17039
116. Reck M Bondarenko I Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial Ann Oncol 2013 24 1 75 83
117. Ott P A Fernandez M EE Hiret S, et al. Pembrolizumab (MK-3475) in patients with extensive-stage small cell lung cancer: Preliminary safety and efficacy results from KEYNOTE-028 J Clin Oncol 2015 33 (15S): 400s [ abstract 7502]
118. Antonia S J Bendell J C Taylor M H, et al. Phase I/II study of nivolumab with or without ipilumumab for treatment of recurrent small cell lung cancer: CA209-032 J Clin Oncol 2015 33 (15S): 400s [ abstract 7503]
119. Hou J M Krebs M G Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer J Clin Oncol 2012 30 5 525 532